Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Neil McAuslane"'
Publikováno v:
International Journal of Health Policy and Management, Vol 11, Iss 2, Pp 128-137 (2022)
BackgroundThe development of a medicine is not only underpinned by good science but also by Quality DecisionMaking Practices (QDMPs). Indeed, it is important to ensure that all organisations involved in the lifecycle of medicines are aligning their p
Externí odkaz:
https://doaj.org/article/012254db8d8243e3bca7d76701cfb7f2
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The target product profile (TPP) outlines the desired profile of a target product aimed at a particular disease and is used by companies to plan clinical development. Considering the increasing importance of health technology assessment (
Externí odkaz:
https://doaj.org/article/d25677fa677b4d608b735843d9929e4a
Autor:
Ting Wang, Neil McAuslane, Lawrence Liberti, Helga Gardarsdottir, Wim Goettsch, Hubert Leufkens
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: Health technology assessment (HTA) has increased in importance in supporting payer decision making by assessing the relative effectiveness and cost effectiveness of new medicines. Thus, pharmaceutical companies need to address the HTA req
Externí odkaz:
https://doaj.org/article/efacf8fe068f4a06b44b5b0215ab47b5
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1 (2020)
Background The Caribbean Regulatory System is a centralized medicine assessment procedure established to serve the needs of the Member States of the CARICOM region. In order to better understand the effectiveness and efficiency of the processes imple
Externí odkaz:
https://doaj.org/article/3dc04d8cfa044fad9adcdfeb78dbf0ef
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Introduction: The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality of their decision-making processes a
Externí odkaz:
https://doaj.org/article/212a9fd4bd5444419eca09717c84d9be
Publikováno v:
Pharmaceutical Medicine. 37:251-260
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bfb62fa30dd1fe27be597fea837fd8a
https://doi.org/10.1007/s40290-023-00472-0
https://doi.org/10.1007/s40290-023-00472-0
Autor:
Hajed M. Hashan, Sarah K. Al-Muteb, Ibrahim A. Alismail, Othman N. Alsaleh, Zakiya M. Alkherb, Neil McAuslane, Stuart R. Walker
Publikováno v:
Pharmaceutical Medicine. 36:223-231
The Gulf Centralised Committee for Drug Registration (GCC-DR), as part of the Gulf Health Council (GHC), enables the consolidated registration of pharmaceutical products throughout the member states of the Gulf Cooperation Council.The objectives of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d4936def64fdf7ba9891c856ce5e68
https://doi.org/10.1007/s40290-022-00432-0
https://doi.org/10.1007/s40290-022-00432-0
Publikováno v:
International Journal of Technology Assessment in Health Care. 39
Background Multi-stakeholder interactions have evolved at product and policy levels. There is a need to assess the current and future landscape of interactions between companies, and regulatory and HTA agencies to address challenges and identify area
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58df9e1256102a5f1a60a14c6be38ea4
https://doi.org/10.1017/s0266462323000144
https://doi.org/10.1017/s0266462323000144
Publikováno v:
International Journal of Technology Assessment in Health Care. 38:S107-S108
IntroductionThe orphan designation has been used by the European Medicines Agency to incentivize the development of drugs treating rare diseases with high-unmet medical needs by supporting their development process and economic returns. This study ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc4a615ef83db57fc245bf2d46b7de5a
https://doi.org/10.1017/s0266462322003063
https://doi.org/10.1017/s0266462322003063
Autor:
Ting Wang, Anke M. Hövels, Iga Lipska, Neil McAuslane, Lawrence Liberti, Hubert G. M. Leufkens
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:332-348
ObjectivesThe objectives of the study were to establish a benchmarking tool to collect metrics to enable increased clarity regarding the differences and similarities across health technology assessment (HTA) agencies, to assess performance within and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e690569011de33be84d18957ffb8a5
https://doi.org/10.1017/s0266462320000598
https://doi.org/10.1017/s0266462320000598